vs
Steris（STE）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是Steris的1.4倍（$2.1B vs $1.5B），Steris净利率更高（12.9% vs 11.4%，领先1.5%），捷迈邦美同比增速更快（9.3% vs 9.2%），捷迈邦美自由现金流更多（$245.9M vs $199.5M），过去两年Steris的营收复合增速更高（15.8% vs 3.7%）
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
STE vs ZBH — 直观对比
营收规模更大
ZBH
是对方的1.4倍
$1.5B
营收增速更快
ZBH
高出0.1%
9.2%
净利率更高
STE
高出1.5%
11.4%
自由现金流更多
ZBH
多$46.4M
$199.5M
两年增速更快
STE
近两年复合增速
3.7%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $2.1B |
| 净利润 | $192.9M | $238.3M |
| 毛利率 | 43.8% | 64.6% |
| 营业利润率 | 18.3% | 17.9% |
| 净利率 | 12.9% | 11.4% |
| 营收同比 | 9.2% | 9.3% |
| 净利润同比 | 11.2% | 30.5% |
| 每股收益（稀释后） | $1.96 | $1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STEZBH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.5B | $2.2B | ||
| Q3 25 | $1.5B | $2.0B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.5B | $1.9B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $1.3B | $1.9B |
净利润STEZBH
| Q1 26 | — | $238.3M | ||
| Q4 25 | $192.9M | $139.4M | ||
| Q3 25 | $191.9M | $230.9M | ||
| Q2 25 | $177.4M | $152.8M | ||
| Q1 25 | $145.7M | $182.0M | ||
| Q4 24 | $173.5M | $239.5M | ||
| Q3 24 | $150.0M | $249.1M | ||
| Q2 24 | $145.4M | $242.8M |
毛利率STEZBH
| Q1 26 | — | 64.6% | ||
| Q4 25 | 43.8% | 64.7% | ||
| Q3 25 | 44.2% | 72.1% | ||
| Q2 25 | 45.1% | 71.5% | ||
| Q1 25 | 43.3% | 71.2% | ||
| Q4 24 | 44.5% | 71.0% | ||
| Q3 24 | 43.6% | 70.5% | ||
| Q2 24 | 44.7% | 71.5% |
营业利润率STEZBH
| Q1 26 | — | 17.9% | ||
| Q4 25 | 18.3% | 6.9% | ||
| Q3 25 | 18.2% | 17.6% | ||
| Q2 25 | 17.7% | 14.4% | ||
| Q1 25 | 14.6% | 15.3% | ||
| Q4 24 | 17.9% | 19.2% | ||
| Q3 24 | 16.5% | 15.3% | ||
| Q2 24 | 14.5% | 18.1% |
净利率STEZBH
| Q1 26 | — | 11.4% | ||
| Q4 25 | 12.9% | 6.2% | ||
| Q3 25 | 13.1% | 11.5% | ||
| Q2 25 | 12.8% | 7.4% | ||
| Q1 25 | 9.8% | 9.5% | ||
| Q4 24 | 12.7% | 11.8% | ||
| Q3 24 | 11.3% | 13.7% | ||
| Q2 24 | 11.4% | 12.5% |
每股收益（稀释后）STEZBH
| Q1 26 | — | $1.22 | ||
| Q4 25 | $1.96 | $0.71 | ||
| Q3 25 | $1.94 | $1.16 | ||
| Q2 25 | $1.79 | $0.77 | ||
| Q1 25 | $1.48 | $0.91 | ||
| Q4 24 | $1.75 | $1.18 | ||
| Q3 24 | $1.51 | $1.23 | ||
| Q2 24 | $1.46 | $1.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $423.7M | $424.2M |
| 总债务越低越好 | $1.9B | $7.5B |
| 股东权益账面价值 | $7.2B | $12.7B |
| 总资产 | $10.6B | $22.7B |
| 负债/权益比越低杠杆越低 | 0.27× | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资STEZBH
| Q1 26 | — | $424.2M | ||
| Q4 25 | $423.7M | $591.9M | ||
| Q3 25 | $319.2M | $1.3B | ||
| Q2 25 | $279.7M | $556.9M | ||
| Q1 25 | $171.7M | $1.4B | ||
| Q4 24 | $155.2M | $525.5M | ||
| Q3 24 | $172.2M | $569.0M | ||
| Q2 24 | $198.3M | $420.1M |
总债务STEZBH
| Q1 26 | — | $7.5B | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
股东权益STEZBH
| Q1 26 | — | $12.7B | ||
| Q4 25 | $7.2B | $12.7B | ||
| Q3 25 | $7.0B | $12.8B | ||
| Q2 25 | $7.0B | $12.5B | ||
| Q1 25 | $6.6B | $12.4B | ||
| Q4 24 | $6.4B | $12.5B | ||
| Q3 24 | $6.6B | $12.4B | ||
| Q2 24 | $6.4B | $12.7B |
总资产STEZBH
| Q1 26 | — | $22.7B | ||
| Q4 25 | $10.6B | $23.1B | ||
| Q3 25 | $10.4B | $23.5B | ||
| Q2 25 | $10.4B | $22.9B | ||
| Q1 25 | $10.1B | $22.2B | ||
| Q4 24 | $10.0B | $21.4B | ||
| Q3 24 | $10.2B | $21.7B | ||
| Q2 24 | $10.1B | $21.5B |
负债/权益比STEZBH
| Q1 26 | — | 0.59× | ||
| Q4 25 | 0.27× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $298.2M | $359.4M |
| 自由现金流经营现金流 - 资本支出 | $199.5M | $245.9M |
| 自由现金流率自由现金流/营收 | 13.3% | 11.8% |
| 资本支出强度资本支出/营收 | 6.6% | — |
| 现金转化率经营现金流/净利润 | 1.55× | 1.51× |
| 过去12个月自由现金流最近4个季度 | $917.1M | $1.4B |
8季度趋势，按日历期对齐
经营现金流STEZBH
| Q1 26 | — | $359.4M | ||
| Q4 25 | $298.2M | $517.4M | ||
| Q3 25 | $287.8M | $418.7M | ||
| Q2 25 | $420.0M | $378.2M | ||
| Q1 25 | $260.8M | $382.8M | ||
| Q4 24 | $332.8M | $506.3M | ||
| Q3 24 | $250.7M | $395.7M | ||
| Q2 24 | $303.7M | $369.4M |
自由现金流STEZBH
| Q1 26 | — | $245.9M | ||
| Q4 25 | $199.5M | $442.6M | ||
| Q3 25 | $201.3M | $363.7M | ||
| Q2 25 | $326.4M | $328.1M | ||
| Q1 25 | $189.9M | $338.2M | ||
| Q4 24 | $243.6M | $454.8M | ||
| Q3 24 | $148.8M | $351.2M | ||
| Q2 24 | $195.7M | $316.7M |
自由现金流率STEZBH
| Q1 26 | — | 11.8% | ||
| Q4 25 | 13.3% | 19.7% | ||
| Q3 25 | 13.8% | 18.2% | ||
| Q2 25 | 23.5% | 15.8% | ||
| Q1 25 | 12.8% | 17.7% | ||
| Q4 24 | 17.8% | 22.5% | ||
| Q3 24 | 11.2% | 19.3% | ||
| Q2 24 | 15.3% | 16.3% |
资本支出强度STEZBH
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 3.3% | ||
| Q3 25 | 5.9% | 2.7% | ||
| Q2 25 | 6.7% | 2.4% | ||
| Q1 25 | 4.8% | 2.3% | ||
| Q4 24 | 6.5% | 2.5% | ||
| Q3 24 | 7.7% | 2.4% | ||
| Q2 24 | 8.4% | 2.7% |
现金转化率STEZBH
| Q1 26 | — | 1.51× | ||
| Q4 25 | 1.55× | 3.71× | ||
| Q3 25 | 1.50× | 1.81× | ||
| Q2 25 | 2.37× | 2.48× | ||
| Q1 25 | 1.79× | 2.10× | ||
| Q4 24 | 1.92× | 2.11× | ||
| Q3 24 | 1.67× | 1.59× | ||
| Q2 24 | 2.09× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
ZBH
暂无分部数据
